ArticleBMC neurology2026
Central nervous symptoms as the prominent manifestation of Sjögren's disease (SjD): a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSjögren's disease (SjD) is a chronic autoimmune disease featured by lymphocytic infiltration of exocrine glands and numerous organ involvements, but central nervous system involvement is relatively rare. Due to the variety of symptoms, diagnosis is particularly difficult under certain conditions, which may delay the optimal timing of treatment. Increased clinical awareness and effective pharmacotherapies are urgently needed. CASE PRESENTATION: A case of a 39-year-old female was initially considered to have an intracranial occupancy based upon rapidly progressing nervous symptoms including intermittent fever, parieto-occipital headache, numbness and weakness in the hand, blurred vision, memory impairment and imaging findings, but it was ultimately clarified that she had SjD involving nervous system, with immunological results showing positive antinuclear antibodies (1:640) and anti-SSA/SSB antibodies (+++) in serum and pathological findings suggesting vasculitis of brain. Finally, she was successfully treated with rituximab.
conclusionsThe onset of SjD may even only manifest as neurological symptoms, which could be easily confused with other systemic or neurological diseases, thus demanding careful differential diagnosis through a detailed medical history and immunological, even pathological examinations to clarify the etiology. Rituximab is an effective treatment option for SjD involving nervous systems, which is an option not commonly featured in standard treatment protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.